The Legal Cannabis Market was valued at USD 69.7 billion in 2024. It is estimated at USD 89.0 billion for 2026 and projected to reach USD 216.8 billion by 2033, a CAGR of 13.5% from 2025 to 2033, according to Grand View Research. North America led with a 71.7% revenue share in 2024. Three questions shape the market: how fast it is growing, which laws allow it to grow, and what it returns to the economy.

Legal Cannabis Market Size and Projections

The USD 69.7 billion base in 2024 is forecast to more than triple by 2033. The projected USD 89.0 billion in 2026 is the near-term checkpoint for anyone tracking whether the curve is holding.

The segment split shows where the money sits. Marijuana held the largest source share at 60.8% in 2024, and CBD led derivatives at 66.9%. Medical use led end-use at 63.6%. Hemp is expected to post the fastest source-level CAGR, driven by demand in food, textiles, paper, building materials, and absorbent products. Regionally, Europe is flagged as the fastest-growing market, Canada is expected to be the fastest-growing country market, and Asia is also projected for rapid growth.

The figures in this article draw on Grand View Research’s market analysis. Continue your research with their Prism AI tool for more data and insights.

Why the numbers hold up

The largest revenue segment is CBD, the non-psychoactive compound, while public debate centers on THC. The least controversial compound earns the most, and the controversial one is growing through new formats. Trulieve’s THC-infused energy drink Upward, launched in July 2025 in Florida and Illinois, is one example.

Demand also tracks disease burden more than lifestyle trends. Cancer caused nearly 20 million new cases and 9.7 million deaths worldwide in 2022, and projections reach 33 million cases and 18.2 million deaths by 2050. Cannabis is used for cancer-related pain, chemotherapy-induced nausea, and appetite loss. The FDA has approved Syndros and Marinol for chemotherapy side effects. A CDC article cited in the report puts chronic pain at 24.3% of adults in North America in 2023, which supports demand for pain alternatives.

Download a free sample report or claim your copy of this full market intelligence report

Legal Status Across the U.S.

The U.S. is a patchwork. Cannabis is legal in most states, but the report notes that medical use is still restricted in several, so access depends on the state. Recent changes show how fast that is moving:

• March 2023: Kentucky legalized medical cannabis.
• April 2023: Delaware legalized adult use.
• August 2023: Minnesota legalized adult use.

Once adult-use laws pass, patient preference tends to shift from medical to recreational channels because of lower cost and easier access. The market therefore does not simply expand when a state legalizes. Its mix changes. Medical use led in 2024, but recreational use is expected to grow significantly as attitudes shift and products such as beverages, edibles, and vapes gain traction. Cannabis tourism adds to demand where laws allow it.

Rules outside the U.S. matter too. In April 2025, Canada relaxed packaging and labeling restrictions, allowing transparent packaging and branded lids, and streamlined licensing for micro-cultivators and micro-processors. Looser rules lower the cost of doing business, which tends to favor smaller producers.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Legal Cannabis Market Economy and Employment

The clearest economic figure in the report is tax and licensing revenue. Washington state reported USD 468.5 million from legal cannabis taxes, license fees, and penalties in fiscal year 2023. The report breaks down where it went: USD 230.0 million to Basic Health, USD 119.0 million to the General Fund, USD 48.0 million to the Washington State Health Care Authority, USD 22.0 million to local governments, USD 11.0 million to the Department of Health, and USD 2.4 million to the Washington State Patrol. Most of the allocated money goes to health programs and general public spending, which explains why governments favor regulated sales over an illicit market.

The source does not publish job counts, so employment is best read through business activity. In June 2025, Vireo Growth completed a USD 102 million acquisition of Missouri-based Proper Brands, covering 11 dispensaries and a cultivation and manufacturing site of over 100,000 square feet. Vireo also acquired Nevada’s Deep Roots Holdings, which operates ten dispensaries and a 54,000-square-foot facility. Operations like these need cultivation, extraction, retail, and compliance staff. Training is following: in December 2023, Bellarmine University launched a cannabis education certificate program covering agriculture, business, medicine, and law.

The Legal Cannabis Market is consolidating through M&A while expanding abroad. Cronos Group partnered with Switzerland’s Dascoli Pharma AG in July 2025 to distribute PEACE NATURALS medical cannabis. Tilray Medical gained Italian approval to import and distribute three medical flower varieties in June 2025. The leading participants include Tilray Brands, Canopy Growth, Aurora Cannabis, Jazz Pharmaceuticals, Cronos Group, Organigram, Tikun Olam, ENDOCA, Isodiol International, Medical Marijuana Inc., NuLeaf Naturals, and Maricann.

Explore the full list of profiled companies operating in this market with recent strategic initiatives